data + articles · 2 listed
newest 2001spec sheet9 rows
dihydroergocristine is a hydrogenated ergot alkaloid; on its own a minor alpha-adrenergic vasodilator, but far better known as one of the dihydro-ergot components of co-dergocrine (hydergine); standalone evidence is thin and it carries the ergot-class fibrosis risk (it specifically caused reversible interstitial pneumonitis in case series).
- contributes to the vasoactive/metabolic effects of the co-dergocrine (hydergine) mixture
- standalone alpha-adrenergic vasodilator with a long (if dated) regional history
- no robust standalone efficacy evidence; benefit is inferred from the mixture
Mechanism
dihydroergocristine is a hydrogenated ergoline whose pharmacology is the usual ergot mix: alpha-1 adrenoceptor antagonism (the source of its vasodilator, blood-flow-raising reputation) layered with partial-/ activity at receptors and weak effects. it matters mostly as a constituent: co-dergocrine, the drug sold as hydergine, is a fixed mixture of dihydroergocornine, dihydroergocristine and the alpha/beta dihydroergocryptines, and essentially all of the credible clinical evidence in this corner of the ergot world attaches to that balanced mixture rather than to dihydroergocristine in isolation (olin et al, cochrane, doi 10.1002/14651858.CD000359). as a standalone it has been used regionally as a vasodilator, sometimes combined with the rauwolfia alkaloid raubasine, but without a modern trial base. the safety picture is the reason to be cautious: dihydroergocristine was one of the specific agents in pfitzenmeyer's case series of ergoline-induced pleuropulmonary disease, producing reversible interstitial pneumonitis (doi 10.1183/09031936.96.09051013), and it was included in the 2013 european ergot-derivative restrictions. bottom line: it's a real molecule with a real mechanism, but the honest evidentiary weight lives in the hydergine mixture, not here.
receptor fingerprint
Alpha-1 adrenoceptorantagonist
receptors (/2)partial agonist / antagonist (ergoline)
receptorweak partial agonist
Neuronal metabolismenhances (claimed)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Dihydroergocristine is a hydrogenated ergot alkaloid (a component of ergoloid mesylates/Hydergine) used historically for cerebrovascular insufficiency and dementia, and at standard doses it is comparatively mild because hydrogenation strips the strong vasoconstrictor action of natural ergots. Common adverse effects are largely gastrointestinal and vasomotor; nausea, vomiting, flushing, headache, dizziness, nasal congestion, blurred vision, bad taste, and postural (orthostatic) hypotension from its vasodilatory action.
As an ergot derivative it should be used cautiously given the class association with rare but serious vasospastic reactions, and the very rare reports of myocardial ischemia, arrhythmia, and hallucination warrant attention in susceptible patients. Efficacy for its historical cognitive indications was never convincingly established, so benefit is uncertain even as risk stays real. Ergot alkaloids also interact with other vasoconstrictors and certain CYP3A4 inhibitors, which is a meaningful interaction caution.
Subjective profileweighing the evidence above
Not worth seeking out. Standalone evidence barely exists, its reputation is borrowed from the old Hydergine mixture, and it carries the ergot class fibrosis risk along with reported cases of reversible lung inflammation.
Resources
This entry is here for reference.
Research
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is dihydroergocristine?
it's a hydrogenated ergot alkaloid, best known as one of the three-to-four dihydro-ergot components that make up co-dergocrine (hydergine). on its own it has been marketed in some countries as a vasodilator (e.g. diertina) and paired in combination products with the alpha-blocker raubasine for circulatory complaints. mechanistically it's an ergoline: an alpha-adrenergic antagonist with the usual serotonin and dopamine dabbling of the class.
does it have good standalone evidence?
not really; that's the honest read. the strong clinical evidence in this family attaches to the co-dergocrine mixture (hydergine) as a whole, not to dihydroergocristine used alone. as a single agent it's mostly older, regional vasodilator use without the modern trial base you'd want. treat any 'nootropic' framing of the standalone molecule with skepticism.
is it the same as hydergine?
no; it's a piece of hydergine. co-dergocrine (hydergine) is a defined mixture of dihydroergocornine, dihydroergocristine and the two dihydroergocryptine isomers. so dihydroergocristine contributes to hydergine's activity, but taking it alone is not the same as taking the balanced mixture that the trials studied.
what's the safety concern?
the ergot-class one, and this molecule specifically flagged it: pfitzenmeyer et al documented reversible interstitial pneumonitis in patients on dihydroergocristine, part of a broader pattern of pleuropulmonary fibrosis with chronic ergolines (doi 10.1183/09031936.96.09051013). add the usual ergot risks (fibrosis of heart valves/retroperitoneum, ergotism, vasospasm) with long-term use. the 2013 ema ergot review swept it up along with the rest of the class.
is it used today?
rarely, and mostly regionally or as a hydergine component rather than as a standalone star. the vasodilator ergots as a group have faded, both because the benefit for 'poor circulation' and cognitive symptoms is modest and because the fibrosis risk isn't worth it for soft indications.
why is it on this list?
because the brief covers the nootropic/vasoactive ergot derivatives, and dihydroergocristine is one of the named building blocks of that family (a hydergine component and a standalone vasoactive ergoline). it's included for completeness and honesty about where the evidence actually sits, which is: strong for the mixture, thin for the isolated molecule.